Zhejiang Taimei Medical Technology Co., Ltd. logo

Zhejiang Taimei Medical Technology Co., Ltd.

2576.HK

HKSETechnologySoftware - Application

Latest quote

HK$5.395

−HK$0.15 · -2.71%

Aug 24, 11:56 AM HKT

2576.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.

Industry
Software - Application
Sector
Technology
Headquarters
CN
CEO
Wan Yunyun
Listed since
Oct 8, 2024
Employees
681

Market position

Day range

Current HK$5.395

52-week range

Current HK$5.395

Open
HK$5.60
Previous close
HK$5.545
Volume
280.4K
0.35× average
Average volume
812.4K
Average daily volume
Market cap
3.04B HKD
Beta
0.01
Market reference 1
50-day average
HK$5.8397
-7.62% below average
200-day average
HK$4.7971
+12.46% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.44B CNY
P/E (TTM)
-129.9×
P/B (TTM)
2.32×
P/S (TTM)
9.72×
EV / EBITDA
-49.5×
Earnings yield
-2.08%
Free cash flow yield
-2.15%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
43.74%
Operating margin
-13.72%
Net margin
-7.47%
Return on equity
-3.72%
Return on assets
-2.68%
Return on invested capital
-4.78%

Financial health

Debt / equity
0.05×
Current ratio
4.47×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends58%-3%-63%-124%Gross margin, FY2021: 35.09%Gross margin, FY2022: 33.76%Gross margin, FY2023: 31.23%Gross margin, FY2024: 40.81%Gross margin, FY2025: 42.44%Operating margin, FY2021: -108.46%Operating margin, FY2022: -80.62%Operating margin, FY2023: -69.20%Operating margin, FY2024: -45.80%Operating margin, FY2025: -12.32%Net margin, FY2021: -102.88%Net margin, FY2022: -75.18%Net margin, FY2023: -60.51%Net margin, FY2024: -38.94%Net margin, FY2025: -8.36%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 35.09%. Gross margin FY2022 33.76%. Gross margin FY2023 31.23%. Gross margin FY2024 40.81%. Gross margin FY2025 42.44%. Operating margin FY2021 -108.46%. Operating margin FY2022 -80.62%. Operating margin FY2023 -69.20%. Operating margin FY2024 -45.80%. Operating margin FY2025 -12.32%. Net margin FY2021 -102.88%. Net margin FY2022 -75.18%. Net margin FY2023 -60.51%. Net margin FY2024 -38.94%. Net margin FY2025 -8.36%.

Income trends

Revenue

499.28M CNY-9.41%

Operating income

−61.5M CNY+75.64%

Net income

−41.74M CNY+80.55%
Income trends across reported periods681.01M CNY249.51M CNY−182M CNY−613.51M CNYRevenue, FY2021: 466.18M CNYRevenue, FY2022: 549.22M CNYRevenue, FY2023: 573.14M CNYRevenue, FY2024: 551.16M CNYRevenue, FY2025: 499.28M CNYOperating income, FY2021: −505.63M CNYOperating income, FY2022: −442.78M CNYOperating income, FY2023: −396.59M CNYOperating income, FY2024: −252.45M CNYOperating income, FY2025: −61.5M CNYNet income, FY2021: −479.61M CNYNet income, FY2022: −412.91M CNYNet income, FY2023: −346.78M CNYNet income, FY2024: −214.61M CNYNet income, FY2025: −41.74M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 466.18M CNY. Revenue FY2022 549.22M CNY. Revenue FY2023 573.14M CNY. Revenue FY2024 551.16M CNY. Revenue FY2025 499.28M CNY. Operating income FY2021 −505.63M CNY. Operating income FY2022 −442.78M CNY. Operating income FY2023 −396.59M CNY. Operating income FY2024 −252.45M CNY. Operating income FY2025 −61.5M CNY. Net income FY2021 −479.61M CNY. Net income FY2022 −412.91M CNY. Net income FY2023 −346.78M CNY. Net income FY2024 −214.61M CNY. Net income FY2025 −41.74M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue499.28M CNY551.16M CNY573.14M CNY549.22M CNY466.18M CNY
Cost of goods sold287.37M CNY326.21M CNY394.14M CNY363.81M CNY301.85M CNY
Gross profit211.91M CNY224.94M CNY179M CNY185.4M CNY163.59M CNY
Research and development76.63M CNY87.05M CNY169.19M CNY233.69M CNY225.09M CNY
Selling, general, and administrative196.78M CNY382.02M CNY384.89M CNY48.99M CNY46.22M CNY
Operating expenses273.41M CNY477.4M CNY575.59M CNY628.19M CNY669.97M CNY
Interest income34.72M CNY35.77M CNY41.65M CNY22.88M CNY28.74M CNY
Interest expense811.44K CNY727K CNY1.43M CNY2.68M CNY2.71M CNY
Depreciation and amortization19.46M CNY39.95M CNY51.96M CNY55.53M CNY36.51M CNY
Operating income−61.5M CNY−252.45M CNY−396.59M CNY−442.78M CNY−505.63M CNY
Net income−41.74M CNY−214.61M CNY−346.78M CNY−412.91M CNY−479.61M CNY

Company facts updated Aug 24, 2026.

2576.HK peers

Continue in GoAI

Research 2576.HK

research.disclaimer